Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma

Cancer Letters

Volumn 340, Issue 1, 2013, Pages 124-133

  Wu, Xi ^a   Peng, Meiyu ^a   Huang, Bingqing ^a   Zhang, Huan ^a   Wang, Huafeng ^a   Huang, Biao ^a   Xue, Zhenyi ^a   Zhang, Lijuan ^a   Da, Yurong ^a   Yang, De ^a,b   Yao, Zhi ^a   Zhang, Rongxin ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dormant sarcomas; Immune equilibrium; Immune escape; Immune microenvironment; Immunoediting

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4 CD8 RATIO; CELL FATE; CELL FUNCTION; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FEMALE; GAMMA DELTA T LYMPHOCYTE; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SARCOMA; TH1 TH2 BALANCE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

DORMANT SARCOMAS; IMMUNE EQUILIBRIUM; IMMUNE ESCAPE; IMMUNE MICROENVIRONMENT; IMMUNOEDITING;

ANIMALS; FEMALE; FLOW CYTOMETRY; IMMUNOLOGIC MEMORY; METHYLCHOLANTHRENE; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; SARCOMA, EXPERIMENTAL; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

MURINAE; MUS;

EID: 84883781400     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.038     Document Type: Article

References (49)

1. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
2. Takeda K., Smyth M.J., Cretney E., Hayakawa Y., Kayagaki N., Yagita H., Okumura K. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 2002, 195:161-169.
3. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
4. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
5. Mantovani A., Romero P., Palucka A.K., Marincola F.M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
6. Bindea G., Mlecnik B., Fridman W.H., Pages F., Galon J. Natural immunity to cancer in humans. Curr. Opin. Immunol. 2010, 22:215-222.
7. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pages F., Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 2011, 71:1263-1271.
8. Smyth M.J., Thia K.Y., Street S.E., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Godfrey D.I. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 2000, 191:661-668.
9. Nowak M., Arredouani M.S., Tun-Kyi A., Schmidt-Wolf I., Sanda M.G., Balk S.P., Exley M.A. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS ONE 2010, 5:e11311.
10. Bonneville M., Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 2006, 18:539-546.
11. Todaro M., DyAsaro M., Caccamo N., Iovino F., Francipane M.G., Meraviglia S., Orlando V., La Mendola C., Gulotta G., Salerno A., Dieli F., Stassi G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J. Immunol. 2009, 182:7287-7296.
12. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 2010, 59:1593-1600.
13. Ozao-Choy J., Ma G., Kao J., Wang G.X., Meseck M., Sung M., Schwartz M., Divino C.M., Pan P.Y., Chen S.H. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009, 69:2514-2522.
14. Mizukami Y., Kono K., Kawaguchi Y., Akaike H., Kamimura K., Sugai H., Fujii H. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br. J. Cancer 2008, 98:148-153.
15. Deng L., Zhang H., Luan Y., Zhang J., Xing Q., Dong S., Wu X., Liu M., Wang S. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin. Cancer Res. 2010, 16:4105-4112.
16. Elboim M., Gazit R., Gur C., Ghadially H., Betser-Cohen G., Mandelboim O. Tumor immunoediting by NKp46. J. Immunol. 2010, 184:5637-5644.
17. Diederichsen A.C., Hjelmborg J., Christensen P.B., Zeuthen J., Fenger C. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol. Immunother. 2003, 52:423-428.
18. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Nat. Acad. Sci. USA 2005, 102:18538-18543.
19. Uhr J.W., Marches R. Dormancy in a model of murine B cell lymphoma. Semin. Cancer Biol. 2001, 11:277-283.
20. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7:834-846.
21. Vessella R.L., Pantel K., Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biol. Ther. 2007, 6:1496-1504.
22. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22:329-360.
23. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
24. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., Rubin S.C., Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348:203-213.
25. Schumacher K., Haensch W., Roefzaad C., Schlag P.M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61:3932-3936.
26. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353:2654-2666.
27. Qiu H., Xiao-Jun W., Zhi-Wei Z., Gong C., Guo-Qiang W., Li-Yi Z., Yuan-Fang L., Rajiv-Prasad K. The prognostic significance of peripheral T-lymphocyte subsets and natural killer cells in patients with colorectal cancer. Hepatogastroenterology 2009, 56:1310-1315.
28. Fu J., Xu D., Liu Z., Shi M., Zhao P., Fu B., Zhang Z., Yang H., Zhang H., Zhou C., Yao J., Jin L., Wang H., Yang Y., Fu Y.X., Wang F.S. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007, 132:2328-2339.
29. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., Carbone D.P., Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
30. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., McDermott D., Quiceno D., Youmans A., O'Neill A., Mier J., Ochoa A.C. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
31. Filipazzi P., Valenti R., Huber V., Pilla L., Canese P., Iero M., Castelli C., Mariani L., Parmiani G., Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 2007, 25:2546-2553.
32. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M.L., Knutson K.L., Chen L., Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
33. Youn J.I., Nagaraj S., Collazo M., Gabrilovich D.I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 2008, 181:5791-5802.
34. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
35. Coussens L.M., Zitvogel L., Palucka A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013, 339:286-291.
36. Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., Bicciato S., Bronte V. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 2006, 116:2777-2790.
37. Ko H.J., Lee J.M., Kim Y.J., Kim Y.S., Lee K.A., Kang C.Y. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine. J. Immunol. 2009, 182:1818-1828.
38. Sawanobori Y., Ueha S., Kurachi M., Shimaoka T., Talmadge J.E., Abe J., Shono Y., Kitabatake M., Kakimi K., Mukaida N., Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008, 111:5457-5466.
39. Movahedi K., Guilliams M., Van den Bossche J., Van den Bergh R., Gysemans C., Beschin A., De Baetselier P., Van Ginderachter J.A. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008, 111:4233-4244.
40. Smyth M.J., Crowe N.Y., Godfrey D.I. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 2001, 13:459-463.
41. van den Broek M.E., Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., Melief C.J., Zinkernagel R.M., Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 1996, 184:1781-1790.
42. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Nat. Acad. Sci. USA 1998, 95:7556-7561.
43. Street S.E., Cretney E., Smyth M.J. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001, 97:192-197.
44. Hayakawa Y., Rovero S., Forni G., Smyth M.J. Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Nat. Acad. Sci. USA 2003, 100:9464-9469.
45. Godfrey D.I., Hammond K.J., Poulton L.D., Smyth M.J., Baxter A.G. NKT cells: facts, functions and fallacies. Immunol. Today 2000, 21:573-583.
46. Singh N., Hong S., Scherer D.C., Serizawa I., Burdin N., Kronenberg M., Koezuka Y., Van Kaer L. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 1999, 163:2373-2377.
47. Araki M., Kondo T., Gumperz J.E., Brenner M.B., Miyake S., Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 2003, 15:279-288.
48. Mizgerd J.P., Spieker M.R., Doerschuk C.M. Early response cytokines and innate immunity: essential roles for TNF receptor 1 and type I IL-1 receptor during Escherichia coli pneumonia in mice. J. Immunol. 2001, 166:4042-4048.
49. Xiang R., Lode H.N., Gillies S.D., Reisfeld R.A. T cell memory against colon carcinoma is long-lived in the absence of antigen. J. Immunol. 1999, 163:3676-3683.